Compare AVAL & FOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AVAL | FOLD |
|---|---|---|
| Founded | 1994 | 2002 |
| Country | Colombia | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0B | 4.4B |
| IPO Year | N/A | 2007 |
| Metric | AVAL | FOLD |
|---|---|---|
| Price | $4.17 | $14.30 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 9 |
| Target Price | N/A | ★ $27.56 |
| AVG Volume (30 Days) | 86.8K | ★ 20.8M |
| Earning Date | 02-19-2026 | 02-18-2026 |
| Dividend Yield | ★ 2.59% | N/A |
| EPS Growth | ★ 103.13 | N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $3,419,775,032.00 | $598,704,000.00 |
| Revenue This Year | $46.54 | $21.49 |
| Revenue Next Year | $8.90 | $18.42 |
| P/E Ratio | $11.62 | ★ N/A |
| Revenue Growth | 17.39 | ★ 21.28 |
| 52 Week Low | $2.12 | $5.51 |
| 52 Week High | $4.50 | $14.36 |
| Indicator | AVAL | FOLD |
|---|---|---|
| Relative Strength Index (RSI) | 54.90 | 90.18 |
| Support Level | $4.00 | $14.26 |
| Resistance Level | $4.17 | $14.35 |
| Average True Range (ATR) | 0.10 | 0.06 |
| MACD | -0.00 | -0.05 |
| Stochastic Oscillator | 68.52 | 67.50 |
Grupo Aval Acciones y Valores SA is a Colombian financial services company. Its segments include: Banking Services segment comprises Banking Services, fund management and trust businesses, storage companies and entities that manage low-value payment systems. Merchant Banking segment comprises Financial Sector (trust and brokerage), Gas and Energy Sector (includes natural gas and energy transportation and distribution businesses), Infrastructure Sector (includes road infrastructure projects, construction services, and operation and maintenance), Hotel Sector (includes hospitality services), Agribusiness Sector (includes palm oil, rubber and rice businesses). Pension and Severance Fund Management" segment comprise administrator of pension and severance funds; and Holding segment.
Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.